(19)
(11) EP 4 185 313 A1

(12)

(43) Date of publication:
31.05.2023 Bulletin 2023/22

(21) Application number: 21743216.0

(22) Date of filing: 23.07.2021
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
A61K 39/395(2006.01)
A61P 37/06(2006.01)
A61K 38/17(2006.01)
C12N 5/10(2006.01)
 A61K 39/00(2006.01)
A61P 35/00(2006.01)
C07K 16/24(2006.01)
C07K 14/47(2006.01)
C12N 15/09(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/244; A61K 39/39541; A61P 37/06; A61P 35/00; A61K 2039/5156; C07K 2319/03; C07K 2317/622; A61K 39/001112; A61K 2039/55527; A61K 38/1709; C12N 2510/00; C12N 5/0636; A61K 48/005
 
C-Sets:
  1. A61K 39/39541, A61K 2300/00;
  2. A61K 39/001112, A61K 2300/00;
(86) International application number:
PCT/EP2021/070765
(87) International publication number:
WO 2022/018295 (27.01.2022 Gazette 2022/04)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 24.07.2020 EP 20187684

(71) Applicant: AB2 Bio SA
1015 Lausanne (CH)

(72) Inventors:
  • SCHIFFRIN, Eduardo
    1015 Lausanne (CH)
  • SOLDAN, Michael
    1015 Lausanne (CH)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstraße 3
81675 München
81675 München (DE)

   


(54) AVOIDING OR MINIMIZING SIDE-EFFECTS RELATED TO CAR-T-CELL THERAPY